Sex, n (%)
Female
Male
|
47 (53.4)
41 (46.6)
|
11 (39.3)
17 (60.7)
|
0.193
|
APACHE II*(mean±SD) |
25.78±6.542 |
25.64±6.86 |
0.922 |
Duration of hospitalization before COL therapy, median (min-max) |
18
(3-101) |
14 (4-31) |
0.094 |
Initial serum urea (mg/dL) (mean±SD) |
52.42±23.01 |
42.18±18.59 |
0.034 |
Initial serum creatinine (mg/dL) median (min-max) |
0.8 (0.34-1.2) |
0.64 (0.3-0.95) |
0.001 |
Total colistin day, median (min-max) |
10 (4-23) |
8.5 (4-18) |
0.141 |
Underlying diseases, n (%)
Chronic obstructive pulmonary disease
Diabetes mellitus
Coronary artery disease
Cardiac failure
Chronic renal failure
Immunosupression
Solid organ malignancy
|
53 (60.2)
23 (26.1)
27 (30.7)
23 (26.1)
4 (4.5)
2 (2.3)
|
16 (57.1)
9 (32.1)
8 (28.6)
7 (25)
1 (3.6)
4 (14.3)
|
0.772
0.536
0.832
0.905
1
0.023
|
Vasopressor agent use, n (%) |
33 (37.5) |
10 (35.7) |
0.865 |
Concomitant nephrotoxic agent use, n (%) |
25 (28.4) |
14 (50) |
0.035 |
14-day mortality |
46 (52.3) |
14 (50) |
0.865 |
28-day mortality |
31 (73.8) |
9 (64.3) |
0.511 |
Overall mortality |
84 (95.5) |
23 (82.1) |
0.036 |